Connect with us


AMC Stock: Is It A Buy Now? Here’s What AMC Entertainment Fundamentals, Stock Chart Say




Going to the movies is exciting. But can it match the almost mind-bending action by AMC Entertainment (AMC)? Starting the year of 2021 at 2 a share, AMC stock skyrocketed more than 36-fold to an all-time high of 72.62 on June 2 that same year.


The drama has continued in 2022. Shares sold off on Aug. 22, spurring a temporary halt of trading due to market circuit-breaker news. AMC sank as much as 42% to a session low of 10.46 and broke below the 50-day moving average, a sign of stock weakness. The company’s preferred equity units debuted on the NYSE under the ticker symbol APE.

Holders of AMC’s class A common shares received one APE for every share of AMC owned on Aug. 15. AMC’s management made it clear to investors that AMC stock would feel the impact of what has been dubbed the “APE-split.”


Since then, AMC stock has continued to struggle. Friday morning trading saw shares dive another 7% to 6.62, the lowest level since Feb. 23, 2021. On Monday, AMC bucked the market’s decline, rising nearly 2% and aiming to snap a three-session losing streak.

Prior to this development, AMC stock had already fallen sharply since late November after losing a battle to regain the north side of the pivotal 10-week moving average. Shares also gave back all of its gains from that brief yet powerful rally from a buy point at 14.64 delivered in May to early June of 2021.

Since May of this year, AMC stock had gone on a tear after bottoming out near 10 — perhaps a key psychological price level. And for nearly two weeks in August, shares bullishly traversed across the long-term 200-day moving average.

Put simply, until the recent slide, AMC’s short-term action had been the most bullish since late August to early September of 2021.

Yet at this point, is it time to take any remaining profits off the table? After all, the May 2021 rally displayed elements of a climax run.


Or is it a buy now?

This story examines fundamental, technical and fund ownership factors to determine if the Leawood, Kan., company with 950 theaters and 10,600 screens scores a good probability of making more money for stock traders.

5 NYSE Stocks To Buy And Watch Right Now

In early February, AMC posted revenue in the fourth quarter last year of $1.17 billion, soaring 620% vs. a year earlier, and an adjusted net loss of 11 cents a share. The top line beat a Yahoo Finance consensus estimate of $1.09 billion and a net loss of 26 cents. The blockbuster “Spider-Man: No Way Home” boosted ticket revenues big time. AMC management noted bookings for the upcoming flick “The Batman” in its initial weekend as “very strong.”

For several weeks in March, buyers dominated the stock again. AMC reached a four-month high of 34.33. But as a MarketSmith chart shows, AMC stock bumped its head against the 200-day moving average on a daily chart.


AMC made a better recovery in August. It closed several days above the 200-day line. That had not happened since November.

On Aug. 5, AMC reported another round of stronger quarterly results.

The company posted a net loss of 20 cents a share, down from a loss of 71 cents in the year-ago period. AMC’s net loss shrank to $121.6 million vs. $344 million in the year-ago quarter. Sales soared 162% to $1.17 billion. That marked the fifth quarter in a row of triple-digit top-line gains.

Plus, on a non-GAAP basis, the company generated positive operating cash flow of $52 million. A year earlier, it burned through $127 million in cash at an operating level. The firm also reported $1.18 billion in available liquidity.

“Our Q2 2022 results… prove once again what we have long said, that as Hollywood releases movies with broad consumer appeal, people will flock to see them at movie theatres in huge and eye-popping numbers,” CEO Adam Aron said in a news release. A total 59 million people saw films at AMC theaters globally, up 168% year over year.


Q3 results may arrive around Nov. 8.

5 Nasdaq Stocks To Buy And Watch Now

Going Beyond The Box Office?

Keep in mind that blockbuster movies don’t necessarily lead to an equally sizable windfall for the theater operators.

Robert Marich, author of “Marketing to Moviegoers,” told IBD that “profit excess from ticket sales of blockbuster movies goes disproportionately to Hollywood distributors, because theater percentage of ticket revenue diminishes on a percentage basis.”

AMC is hungry to expand into new revenue streams.


CEO Adam Aron noted six months ago that the company expects to launch a food delivery service with Uber as a partner as early as the second quarter as well as launch an AMC-branded credit card later this year. AMC also noted plans to accept Shiba Inu Dogecoin as payment.

In April, AMC made headlines in another extraordinary way: It bought a 22% stake of Hycroft Mining (HYMC), which operates a precious metals mine in Nevada. The deal gives AMC 23.4 million shares, each share with a warrant to own more shares, in the company. Apparently, the 71,000-acre mine has 15 million ounces of gold deposits and 600 million ounces of mining-worthy silver. HYMC has cooled off after leaping 511% in one week of March alone.

Investor’s Corner: 7 Tips On Outperforming The S&P 500

Technical Action Today

Even though an epic short squeeze rally hit overdrive in January 2021, AMC stock still attracted short sellers during the summer of that year. Now, after a bruising decline since the spring of 2021, have the shorts let up?

Data from brokerage TradeZero for the week ended Aug. 12 shows that short sales picked up to 7,369 shares at an average cost of 24.69 each. In the week ended Aug. 19, TradeZero clients sold 3,087 shares short at an average price of 21.52. That’s tame compared to what TradeZero saw last year. In the week ended July 23, 2021, AMC Entertainment placed 3rd among stocks trading at least $10 a share and getting sold short the most. A total 14,666 short-sale trades crossed the broker’s platform at an average price of 38.18 per share.


In the week ended Sept. 16, AMC did not make TradeZero’s top 10 list in heavily sold-short stocks trading under 10 per share.

Meanwhile, check out the 50-day moving average, drawn in red in all IBD charts. Before the disastrous decline in late August, AMC stock spent six weeks trading mostly above this key technical level. Meanwhile, the 50-day line began rising again. No longer the case today, though.

Why does a rising 50-day line matter? In a nutshell, it means that until the second half of August, AMC’s price trend over the past 2-1/2 months had been up. But the 50-day price trend has definitively turned lower.

Which Way Is The Market Headed Now? Read This Column Every Day

Are The Shorts Covering AMC Stock?

Let’s go back to the prior hyper-fast run during the meme stock boom of 2021.


Prior to the giant gain on June 2, 2021, over just five sessions of trade (May 24 to 28), AMC obliterated the short sellers by rising as much as 203%. In the week ended June 4, AMC stock almost finished up 100% or more for a second straight week. Incredible.

In January 2021, WallStreetBets chat-room traders on Reddit joined in unison in buying shares and bullish call options in AMC stock. They did the same in a band of other companies that had been heavily sold short and struggling.

When a stock shows a high level of short interest and is getting bid up, you can almost count on a chain reaction of buying to occur. Why? Short sellers, betting on a decline in the stock, often have to do an about-face. They cover their short position by buying back shares.

According to MarketSmith, short interest — shares sold short by individual and professional investors —  now runs at 2.3 times AMC stock’s daily average volume of 42.8 million shares. That totals 98 million shares. So, short interest now makes up 19% of the stock’s entire float of 511.7 million — up in recent months, yet still down from 21% in the spring 2021.

Strong profitability in the future could lead to increasing accumulation by large funds and other institutional investors. A powerful rebound could force short sellers to cover their positions, helping to propel shares even higher.


The NYSE publishes data on short sale positions twice a month. Plus, the short coverage ratio can be skewed by dramatic changes in daily share turnover. The above data also does not consider any shares that may have been sold short in dark pools.

Inside Investor’s Corner: What Is Short Interest, And How To Take Advantage Of It

Key IBD Ratings

For now, AMC’s ratings in IBD Stock Checkup are now showing more bearish tints.

They include an improved 58 Earnings Per Share Rating on a scale of 1 to 99. Yet a 15 Composite Rating on a scale of 1 (wizened) to 99 (wizardly) has plunged from a decent score of 76 last month.

Ideally, focus on stocks that show a 90 to 95 Composite score or higher.


Unfortunately, AMC’s movies industry group is sinking back to the bottom of IBD’s 197 industry groups in terms of six-month price-weighted performance. Not good. Check the daily price-weighted performance of all IBD industry groups, plus rankings based on six-month performance, at IBD Data Tables.

Mutual funds owning a stake in AMC have jumped to as high as 662 at the end of the second quarter this year vs. 190 in Q4 of 2020. But in the third quarter, fund owners have sunk to 626.

Relative Strength Sinking Again

When choosing growth stocks for the biggest potential gains based on the CAN SLIM investment paradigm, focus on those with a Composite Rating of 90 or higher. Shooting for a 95 or higher, particularly at the start of a new bull market, is even better.

However, given that AMC stock is a turnaround play, it makes sense to place more emphasis on relative strength. AMC has that in spades.

Earlier in August, AMC held a very respectable 96 Relative Strength Rating. It means AMC stock has outperformed 96% of all stocks in the IBD database over the past 12 months. And the 3-month RS Rating at the time zoomed to a highest possible 99, according to MarketSmith data. Now, those ratings have shrunk to a disappointing 2 and 1, respectively.


The Accumulation/Distribution Rating had risen to a best possible A+ grade on a scale of A to E. Now it’s slipped to a B-.

From March to May 2021, AMC created a boxy cup — plenty of time for a solid cup pattern to form. This pattern produces a proper buy point of 10 cents above the cup’s left-side peak of 14.54 on March 18. So in AMC’s case, the correct entry stood at 14.64.

AMC Action In The First Half Of 2021

AMC had to surpass 14.64 before becoming a new buy. A 20% gain on May 25, 2021, sent shares zooming past the proper buy point. The 5% buy zone goes up to 15.37; the stock quickly got extended.

As always, control your risk. Not all breakouts work, especially when the stock market uptrend goes under pressure or into a correction. The best time to buy? When IBD notes the market in a confirmed uptrend, it signifies that buying demand is healthy among institutional investors.

In stock investing, seek the wind at your back, not in your face.


Back in May 2021, this story suggested watching how AMC stock handles potential upside resistance near 20. In fact, the action since that incredible week ended Jan. 29 molded a deep cup pattern. From that vantage point, AMC delivered a second breakout on May 27, surpassing a new 20.46 buy point with fury.

To get this ideal entry in a cup without handle, simply add 10 cents to the cup’s left-side high — 20.36. On May 27, shares rifled past the 20.46 entry. For a while, AMC refused to look back. Still, with gains of as much as 501% in just two weeks, it made sense to lock in at least partial profits.

AMC Stock In 2022: Is It A Buy Now? Or A Sell?

AMC now sits almost 91% below its 72.62 all-time high set on June 2, 2021. So at the current price level, it does not yet trade at an IBD-style entry point. For those who want to go long, watch to see if a new bullish chart pattern will form.

Three months ago, this story noted it could take a while. Given the stock’s plunge, AMC will need weeks, if not months, to build the right side of that new base in bullish fashion.

Looking at the weekly chart, AMC’s chart shows the general structure of an extreme double bottom. A middle peak of 34.33, standing in between the initial low of 12.90 in mid-March and second low of 9.70 in May, generates a tentative entry at 34.43 for now.


One could also view the price action since April as a super-deep cup pattern. That would produce the same buy point. Please check out this Investor’s Corner for more clues on how to discover a good base.

So, for the cautious investor, AMC is not at a buy now.

For a few days, the weekly chart showed AMC trying to cross a nearly 12-month trendline that connects the September 2021 peak of 52.79 with lower highs in November 2021 (45.95) and the end of April this year (34.33). For the super-aggressive trader, this trendline breakout near 25 offered an uber-speculative entry. Yet the creation of AMC’s “APE-split” new preferred equity units underscores the risk of trendline buy points.

Finally, after you buy any stock with solid prospects, heed the golden rule of investing. Keeping losses small keeps you in the investing game for the long haul.

Please follow Chung on Twitter: @saitochung and @IBD_DChung



Cheap Stocks To Buy: 5 High-Growth Companies To Watch Right Now

What Does A Great Cup With Handle Look Like?

Here Are The Current Long-Term Leaders

What’s New Inside Investor’s Corner


IBD 50 Stocks To Watch

Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.


Microsoft is ready to fight for the $69 billion Activision deal




(Bloomberg) — Microsoft is ready to fight over its $69 billion acquisition of Activision Blizzard Inc. If sued, the US Federal Trade Commission seeks to block the deal, according to a person familiar with the matter.

Most Read from Bloomberg

The Xbox maker has not been in talks with the FTC about remedies or waivers intended to approve the deal, said the person, who asked not to be identified discussing a confidential matter. The person added that FTC staff are wrapping up their investigation and are expected to make a recommendation soon. The FTC commissioners will then vote on whether to file a case.

In the event that the FTC attempts to block the case, Microsoft is preparing to challenge that decision in court, said the person, who requested anonymity speaking about the internal strategy. Jennifer Rhee, an antitrust analyst at Bloomberg Intelligence, said it wouldn’t surprise her if the FTC filed a lawsuit seeking to block the deal, but noted that a court battle would be hard for its enforcers to win and Microsoft could prevail — though the legal battle could stretch. after the deal’s expiry date. Microsoft said it expects to close the deal by June 30.


Another option for Microsoft would be to abandon the deal in the face of a challenge from the Federal Trade Commission. That’s what the company did in 1995 when the US government sued to block its acquisition of Intuit Inc. to manufacture accounting software, as Microsoft said it did not want to face a long legal battle.

Microsoft’s best chance of winning approval to buy Activision is to convince the Biden administration to accept a settlement in which it promises it will not withhold its popular titles from competitors.

But Biden’s antitrust enforcers aren’t fond of such agreements — especially after the Ticketmaster bombing this month brought to light a failed 2010 Justice Department settlement with Live Nation Entertainment Inc.

The FTC takes a tough approach to mergers, especially when it comes to technology and digital markets, but has not indicated whether it plans to sue to block the deal.


In July, the agency filed a lawsuit to block Meta Platforms Inc. From the purchase of the virtual reality application Fitness Inside, claiming that the deal can eliminate competition in a small number of markets, referred to as “emerging competition”.

Microsoft and the Federal Trade Commission declined to comment. Politico reported last week that the Federal Trade Commission is likely to challenge the deal.

The US is one of at least three jurisdictions in which regulators have raised questions about the mega deal, which would dramatically change the landscape of video games and put Microsoft in third place in the global gaming market behind Tencent Holdings Ltd. and Sony Group Corp.

European and UK antitrust regulators have raised questions about whether the popular Call of Duty game franchise will still be available to gamers on Sony’s PlayStation console and whether the merger will allow Microsoft to take a dominant role in the burgeoning but still small market for cloud gaming services.

Microsoft has offered Sony a deal whereby Call of Duty games will be available on PlayStation for ten years, though the companies will need to put in place financial terms to the agreement, the person said.


That person said the software giant advised regulators of these discussions, but did not submit a formal remedy proposal because the review process had not progressed to that stage.

It doesn’t make financial or strategic sense for Microsoft to keep the best-selling PlayStation game franchise because more copies of games are sold on PlayStation than on Xbox and because such a move would anger gamers in a way that could have negative implications for Microsoft. In fact, the acquisition wouldn’t be financially viable for Microsoft if it cut Call of Duty to PlayStation, the person said.

Given the various stages of various investigations around the world, Microsoft will likely discuss this move first with the European Commission, which has set March 23 as the deadline for completing its in-depth review of the deal.

The person said Microsoft hopes the remedies it provides to the European Union will be sufficient globally. However, UK regulators will likely want additional steps from the company.

The UK’s Competition and Markets Authority is currently under an in-depth investigation of the deal after an initial investigation found concerns in game consoles, multi-game subscription services and cloud gaming marketplaces.


The agency said in an October document outlining the scope of its investigation that it was concerned that the deal could allow Microsoft to gain massive market power that would allow it to cut out competitors such as Sony. Although Microsoft promised it would not do so because of reputational damage to Xbox or Call of Duty, the watchdog said it had not identified “convincing evidence” to believe the statements.

Scrutiny of the dominance of big tech companies by the UK agency has intensified since it gained new powers post-Brexit.

Microsoft and the CMA will appear at a key party hearing in mid-December, part of the UK merger process that will allow them to segment and test the parties’ arguments. The agency is expected to make an interim decision by January, and the deadline for a full decision is March.

— With assistance from Emily Birnbaum and Stephanie Bodoni.

(Updates to add the previous acquisition challenge in the fourth paragraph.)


Most Read from Bloomberg Businessweek

© Bloomberg LP 2022

Source link

Continue Reading


ABB agrees to pay $315 million to settle coordinated African bribery investigation (NYSE:ABB)




J2R/iStock Editorial via Getty Images

ABB (New York Stock Exchange:ABB) She agreed to pay more than $315 million The US Department of Justice announced on Friday that it is ending a multinational investigation into the bribery of a high-ranking official of South Africa’s state-owned energy company Ascom.

ABB (ABB) bribed an Eskom official during 2014-2017 “in order to corruptly obtain classified information and win lucrative contracts,” the DOJ said.


The company’s subsidiaries also pleaded guilty to one count of conspiracy to violate anti-bribery provisions of the US Foreign Corrupt Practices Act.

The Justice Department said its decision was coordinated with prosecutors in South Africa and Switzerland, as well as the US Securities and Exchange Commission.

The company said in September it had set aside $325 million to cover costs related to the investigations surrounding the Kozel power plant in South Africa.

ABB’s (ABBQ3 results included above-average revenue and order growth, as well as the best margins seen in many years, but the next 12-18 months should be more challenging for reported revenue and order growth, Stephen Simpson writes in Post analysis on the search for alpha.

Source link


Continue Reading


The Swedish scientist behind the Alzheimer’s drug has big ambitions




As the Japanese pharmaceutical company Eisai presented data this week confirming that it had developed the first drug to slow cognitive decline in Alzheimer’s patients, the audience applauded at a conference in San Francisco.

Among those present was Lars Lanfelt, a little-known Swedish scientist invented The pioneering drug, known as lecanemab, would make a fortune if approved and successfully marketed.

BioArctic, the company he co-founded in 2003 with Pär Gellerfors, struck a licensing deal on monoclonal antibody therapy with Eisai in 2007, giving it hundreds of millions of dollars in milestone payments and royalties on lecanemab sales.

About 55 million people suffer from dementia worldwide and Alzheimer’s disease accounts for up to 70 percent of these cases, according to the World Health Organization.

Analysts predict that the drug could generate sales of up to $10 billion a year, a prospect that would turn BioArctic, as well as Eisai and its co-owner of the drug, US biotech Biogen.


“It’s nice to have money but that’s not what motivates me. It was the science and the opportunity to build a Swedish company,” the 73-year-old told the Financial Times.

“We want [BioArctic] To be a complete pharmaceutical company: this is our ambition.

Brain scan for Alzheimer’s disease © BSIP SA / Alamy

Shares in BioArctic, which has just 75 employees, have more than tripled in value since Eisai revealed in September that lecanemab slowed the rate of cognitive decline in early-stage Alzheimer’s patients by 27 percent.

The Stockholm-listed company is now worth nearly $2 billion and hiring quickly, with ambitions to sell the drug in the Nordic countries where it owns the rights to lecanemab in collaboration with Eisai.

Lecanemab could be approved in the US as early as January under the US Food and Drug Administration’s accelerated approval pathway. But significant hurdles remain, including satisfying doctors’ concerns about its safety and whether the clinical benefits justify the risks from side effects.


Investors also need to be convinced that Eisai will not repeat the mistakes of its partner Biogen, whose shares plunged last year after the failed launch of a similar Alzheimer’s drug called aducanemab that the Japanese group also helped develop.

Biogen initially priced the one-year Aducanemab treatment at $56,000 despite concerns among some health experts who cautioned there was no conclusive evidence of its benefits.

Analysts said this week’s presentation of comprehensive data on licanimab at the Alzheimer’s Clinical Trials Conference in San Francisco, along with the publication of a peer-reviewed article in the New England Journal of Medicine, was a positive development.

“Is it a cure? No. Are we there yet? No, but the data set is clean and shows clear benefit,” said Evan Segerman, an analyst at BMO Capital Markets.

“Based on this data, we are very confident in lecanemab’s approval and eventual reimbursement for the Centers for Medicare and Medicaid Services (CMS),” he said.

BioArctic’s lab and offices in Stockholm, Sweden, where early research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s is carried out © BioArctic / Gustav Gräll

The decision by CMS, the US federal agency that administers national insurance plans, to limit insurance coverage for aducanemab to people undergoing clinical trials hurt the drug’s commercial prospects.

Despite the euphoria in San Francisco this week, some researchers and investors remain cautious about the prospects for lecanemab, a drug that targets sticky plaques called beta-amyloid that build up in the brain. They say the treatment produces only “moderate” clinical benefits compared to a placebo and can cause serious side effects including brain bleeding.

The Death cases Two of the patients treated on likanimab, who were also taking blood-thinning medications, also raised questions about whether large numbers of patients on anticoagulants could eventually be excluded from taking the treatment.

“I suspect that the lack of clear clinical efficacy will mean that licanimab will not be widely taken up in healthcare systems around the world,” said Robert Howard, professor of geriatric psychiatry at University College London.

Lanvelt disputes that assessment, arguing that a 27 percent reduction in the rate of cognitive decline is clinically significant and sufficient for the drug to be approved and released. He said the results of the experiment also confirmed a controversial theory known as the amyloid hypothesis, which states that Alzheimer’s disease is caused primarily by the buildup of plaques in the brain.


“It’s been shown that amyloid beta causes Alzheimer’s disease as much as HIV causes AIDS. I think it’s the same level of evidence,” he claims.

Many researchers disagree that amyloid beta is now proven to be the “primary cause” of Alzheimer’s disease, saying that it is a complex disease with many contributing factors.

“Amyloid beta probably contributes about 30 percent to overall disease, but there are many other disease proteins and other conditions that can increase the rate of decline,” said Dr. Keith Fossell, a UCLA professor of neuroscience. Angeles.

It was Lanvelt’s discovery in the early 1990s of a mutation in the gene responsible for beta-amyloid that helped establish a link between sticky plaques and Alzheimer’s disease. Nearly a decade later while working as a researcher at Karolinska Institutet — a Swedish medical body — he discovered another genetic mutation linked to beta-amyloid clusters called profibrils, the rod-like structures that are a key target for lecanemab.

Dubbed the ‘Arctic mutation’, it led to the discovery of the mAb158 monoclonal antibody, which became lecanemab.


said Lanfelt, who owns 33.5 percent of BioArctic stock but controls 49.3 percent of the biotech’s voting rights. He sold a small portion of his stake in October.

If likanimab turns out to be a commercial success, Lanfelt said, BioArctic will use the proceeds to develop drugs targeting Parkinson’s disease and other disorders of the central nervous system. Despite his age, he said he wants to continue working at BioArctic as long as he can contribute to research.

“You can’t change your lifestyle at this age,” Lanfelt said, adding that he would indulge himself in buying an electric car.

Source link

Continue Reading